Reduce Post-Joint Replacement Surgical Site Infections (SSIs) with Molecular Testing

By the numbers: *burden of joint replacement SSIs*

Over 1 million

Total hip and total knee replacement procedures performed each year in the United States[1]

4%—5%

Readmission rate following lower extremity joint replacement[2]

$60,000—$100,000

Cost of a post-prosthetic knee or hip infection[3]

>1/3 of readmissions due to infection

(63% of infections are due to Staph species like *S. aureus*)[2]

Why Screen for MRSA/*S. aureus* Colonization?

Several evidence based SSI Guidelines support the use of screening

9x

Colonized patients are 9 times more likely to develop an SSI[4]

More than **8 out of 10 cases** of *S. aureus* bacteremia are believed to be caused by a patient's own flora[5,6]

Why Use Molecular (PCR) Testing?

Fast and accurate detection of colonization facilitates targeted infection control practices before surgery

1/3

Standard culture techniques may miss MRSA colonization in up to a third of cases[7,8]

Performing molecular screening during presurgical visit enables same day results

↓ 60%

Enables targeted decolonization reducing SSIs up to 60%[9]

References:

1 Kremers HM, et al. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015;97:1386–1397.
2 Zawadzki N, et al. Readmission due to Infection Following Total Hip and Total Knee Procedures: A Retrospective Study. Ed. Steven Callens. Medicine 96.38 (2017): e7961.
3 The Business Case, A Brief for Hospital Administrators: Prevent Surgical Site Infection for Hip and Knee Arthroplasty. Cambridge, MA: Institute for Healthcare Improvement; 2012. (Available at www.IHI.org)
4 Kluytmans J, et al. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10:505-20.
5 von Eiff C, et al. Nasal carriage as a source of *Staphylococcus aureus* bacteremia. Study Group. N Engl J Med. 2001;344:11-6.
6 Critchley IA. Eradication of MRSA nasal colonization as a strategy for infection prevention. Drug Discov Today Ther Strateg. 2006;3:189-95.
7 Wisniewski, TR. Comparison of Bio-Rad MRSA Select Agar with BBL ChromAgar for MRSA Nares Swab Surveillance Cultures in VISN 12. ASM2008;C-130.
8 Nahimana I, et al. Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant *Staphylococcus aureus*. Clin Microbiol Infect. 2006;12:1168-74.
9 Bode et al, "Preventing Surgical-Site Infections in Nasal Carriers of *Staphylococcus aureus*", NEJM January 2010

For *In Vitro* Diagnostic Use.

CORPORATE HEADQUARTERS
904 Caribbean Drive
Sunnyvale, CA 94089 USA
TOLL FREE **1.888.336.2743**
PHONE **1.408.541.4191**
FAX **1.408.541.4192**

EUROPEAN HEADQUARTERS
Vira Solelh
81470 Maurens-Scopont France
PHONE **33.563.82.53.00**
FAX **33.563.82.53.01**

www.**Cepheid**.com

Cepheid®
A better way.